
|Articles|August 1, 2006
- Pharmaceutical Executive-08-01-2006
- Volume 0
- Issue 0
How Far We've Come
In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.
Advertisement
Articles in this issue
almost 20 years ago
Time Machinealmost 20 years ago
Getting Betteralmost 20 years ago
States Curb Marketingalmost 20 years ago
From the Editor: Take Your Seatalmost 20 years ago
Viewpoint: In Your Wordsalmost 20 years ago
Quiz Answersalmost 20 years ago
Introduction: Pharm Exec at 25Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
2
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
3
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu
4
The Questions You Couldn’t Ask in Time: How Agentic AI Accelerates Market Entry
5




